Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase III Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage III Pancreatic Adenocarcinoma (DIRECT)

Summary

The purpose of this phase III trial is to evaluate the safety and efficacy of NanoKnife IRE with or without modified FOLFIRINOX for stage III pancreatic cancer.

General Information

NCT#: NCT03899636
Study ID: 28-001-ONC
Trial Phase: Phase III

Trial Sponsor: Angiodynamics, Inc.
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Irinotecan, Leucovorin, Irreversible Electroporation (IRE), FOLFIRINOX

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search